Panelists discuss how intravenous administration of immune checkpoint inhibitors creates operational challenges including infusion chair bottlenecks, complex scheduling, venous access difficulties, and time burdens for patients, while subcutaneous formulations offer potential solutions through simplified delivery, reduced infusion center strain, and improved patient convenience.
